Last reviewed · How we verify

Adocia — Portfolio Competitive Intelligence Brief

Adocia pipeline: 2 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 1 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Humulin® Humulin® marketed
Symlin® Symlin® marketed Amylin analog Amylin receptor Diabetes
BioChaperone PDGF-BB BioChaperone PDGF-BB phase 3 Growth factor PDGF receptor (PDGFR) Wound Care / Regenerative Medicine
GlucaGen® HypoKit® GlucaGen® HypoKit® phase 3 Glucagon receptor agonist Glucagon receptor (GCGR) Endocrinology / Diabetes
Humalog® Mix25 Humalog® Mix25 phase 3 Premixed insulin Insulin receptor Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 2 shared drug classes
  2. Cambridge University Hospitals NHS Foundation Trust · 1 shared drug class
  3. Centre Oscar Lambret · 1 shared drug class
  4. Chinese Diabetes Society · 1 shared drug class
  5. Chinese PLA General Hospital · 1 shared drug class
  6. Baylor College of Medicine · 1 shared drug class
  7. Genzyme, a Sanofi Company · 1 shared drug class
  8. Australasian Gastro-Intestinal Trials Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Adocia:

Cite this brief

Drug Landscape (2026). Adocia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/adocia. Accessed 2026-05-13.

Related